Business UpdateApr 22, 2026, 07:03 AM
NeurAxis Adds 4 Insurers for IB-Stim, Covering 1.25M Lives
AI Summary
NeurAxis, Inc. announced that four additional health insurers have adopted medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim. This expansion adds approximately 1.25 million covered lives across five states, increasing patient access to the therapy. The company's CEO highlighted strong momentum in expanding insurance coverage and readiness to capitalize on accelerating demand, while also noting a previously disclosed "going concern" explanatory paragraph from its recent Annual Report on Form 10-K.
Key Highlights
- Four additional health insurers now cover PENFS.
- This expands coverage to approximately 1.25 million lives.
- Coverage includes West Virginia, New Hampshire, South Carolina, Virginia, and Florida.
- IB-Stim is FDA-cleared for functional abdominal pain in patients 8 years and older.
- Company's 10-K includes a "going concern" explanatory paragraph.
Price Impact
More from NRXS